e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Treatment and care of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Medication use in COPD: systematic review and meta-analysis
R. Halbert, J. Natoli, M. Lopez (Los Angeles, CA, Beverly Hills, CA, United States Of America; Montevideo, Uruguay)
Source:
Annual Congress 2007 - Treatment and care of COPD
Session:
Treatment and care of COPD
Session type:
Oral Presentation
Number:
3166
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Halbert, J. Natoli, M. Lopez (Los Angeles, CA, Beverly Hills, CA, United States Of America; Montevideo, Uruguay). Medication use in COPD: systematic review and meta-analysis. Eur Respir J 2007; 30: Suppl. 51, 3166
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Late Breaking Abstract - Developing the pneumonia-optimized ratio for community-acquired pneumonia: an easy, inexpensive and accurate prognostic biomarker
Related content which might interest you:
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005
Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: management
Year: 2010
Misdiagnosed COPD: systematic review and meta-analysis
Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care
Year: 2007
Statin use is associated with reduced mortality in COPD
Source: Eur Respir J 2007; 29: 279-283
Year: 2007
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Global burden of COPD: systematic review and meta-analysis
Source: Eur Respir J 2006; 28: 523-532
Year: 2006
Mechanisms of exacerbation of respiratory symptoms in patients with COPD
Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases
Year: 2006
Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study
Source: Annual Congress 2007 - Asthma subphenotypes
Year: 2007
Where current pharmacological therapies fall short in COPD: symptom control is not enough
Source: Eur Respir Rev 2007; 16: 98-104
Year: 2007
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Can antibiotics prevent acute COPD exacerbation? A systematic review and meta-analysis
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept